代谢学发现,硫转移酶1可能调节素诱导的肝损伤
Ruoyue Huang1, Chunyan Wang1, Zhanxuan E Wu1
1Department of Gastroenterology & Hepatology, Laboratory of Metabolomics and Drug-induced Liver Injury, State Key Laboratory of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, And State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, 610041, China.
Chemico-biological interactions
|November 4, 2024
概括
过量服用胆固醇可以通过减少有益的硫酸代谢产物来损害肝脏. 恢复这些代谢物或向SULT1酶可能可以预防素诱导的肝损伤.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 代谢学 代谢学 代谢学
背景情况:
- 科尔奇辛是一种常见的痛风治疗方法.
- 过量服用胆固醇可以导致肝损伤,但机制尚不清楚.
- 了解菌素的肝毒性对于患者的安全至关重要.
研究的目的:
- 为了研究素诱导的肝损伤的机制.
- 为了确定菌素代谢产物及其对内源代谢产物的影响.
- 探索潜在的治疗策略,以对抗素肝毒性.
主要方法:
- 在体内检查菌素的肝毒性.
- 超高性能液态染色学-质谱学 (UHPLC-MS) 用于代谢分析.
- 研究硫转移酶1 (SULT1) 的作用及其调节.
主要成果:
- 已经确定了17种菌素代谢物,其中包括3种新的硫酸盐形式.
- 胆固醇降低了内源硫酸代谢物,可能是通过SULT1和PPARα.
- 抑制SULT1恶化肝损伤;激活或补充硫酸 (IS) 或硫酸 (PCS) 缓解了它.
结论:
- 胆固醇可以通过抑制SULT1,降低生物活性硫酸代谢物 (IS和PCS) 来引起肝损伤.
- 向SULT1和施用IS/PCS显示了预防菌素肝毒性的潜力.
- 这项研究提供了对素诱导的肝损伤的治疗点的见解.
相关概念视频
Drug Metabolism: Phase II Reactions
3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
153
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
153
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
180
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
180
Drug Metabolism: Phase I Reactions
3.1K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.1K
Regulation of Metabolism
9.3K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.3K
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K


